Kura Oncology Stock Forecast, Price & News

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

How has Kura Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KURA shares have increased by 22.1% and is now trading at $11.78.
View which stocks have been most impacted by COVID-19.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04. During the same period in the prior year, the business posted ($0.42) EPS.
View Kura Oncology's earnings history.

What price target have analysts set for KURA?

5 analysts have issued 1-year price targets for Kura Oncology's stock. Their forecasts range from $21.00 to $80.00. On average, they expect Kura Oncology's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

• Troy E. Wilson, Chairman, President & Chief Executive Officer
• Kathleen Ford, Chief Operating Officer
• Marc Edward Grasso, Chief Financial & Business Officer
• Stephen Dale, Chief Medical Officer
• Mollie Leoni, Vice President-Clinical Development

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include Apellis Pharmaceuticals (APLS), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), OPKO Health (OPK), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Insmed (INSM), Cytokinetics (CYTK), Zentalis Pharmaceuticals (ZNTL), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Sage Therapeutics (SAGE), I-Mab (IMAB), Indivior (INVVY) and Arcus Biosciences (RCUS).
View all of KURA's competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Asymmetry Capital Management L.P. (0.75%), Russell Investments Group Ltd. (0.09%), Denali Advisors LLC (0.01%) and Lindbrook Capital LLC (0.00%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which major investors are buying Kura Oncology stock?

KURA stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Russell Investments Group Ltd., Denali Advisors LLC, and Lindbrook Capital LLC.
View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $11.78.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $784.03 million. The company earns $-89.63 million in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 89 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].